Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 44, Issue 3, Pages 197-207Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyt201
Keywords
breast cancer; antiangiogenic therapy; predictive biomarker; clinical trial
Categories
Funding
- Innovative Techno-Hub for Integrated Medical Bio-imaging of the Project for Developing Innovation Systems, from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan
- Department of Breast Surgery, Graduate School of Medicine, Kyoto University
Ask authors/readers for more resources
The development of new blood vessels is a crucial step in breast cancer growth, progression and dissemination, making it a promising therapeutic target. Breast cancer has a heterogeneous nature and the diversity of responsible angiogenic pathways between different tumors has been studied for many years. Inhibiting different targets in these pathways has been under investigation in preclinical and clinical studies for more than decades, among which antibody against vascular endothelial growth factor is the most studied. However, the clinical impact from antiangiogenic treatment alone or in combination with standard chemotherapeutic regimens has been relatively small till today. In this review, we summarize the most clinically relevant data from breast cancer treatment clinical trials and discuss safety and efficacy of common antiangiogenic therapies as well as biological predictive markers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available